


SL-46. EGFR/PDGFR inhibitors

The activation of platelet-derived growth factor (PDGF) receptor A (PDGFRA), PDGF receptor B (PDGFRB), and epidermal growth factor receptor (EGFR), plays a critical role in oncogenesis and tumor angiogenesis. Recent studies suggest that therapeutic agents directed against these growth factors induce antiproliferative effects in brain tumor cells thus providing new

opportunities for the treatment of patients with certain rare forms of tumors [1,2]. Screening of the ASINEX Biodesign™ Kinase library has revealed a number of potent ($IC_{50} < 1\mu M$) inhibitors of EGFR and PDGFR α/β . This library is a useful starting point for kinase-oriented research and drug discovery.



Signature Library 46

Formats	Supplementary Information
80 compounds per plate 0.1 mg; 1 mg; 2 mg dry film/powder 0.1 μ mol; 1 μ mol DMSO solutions	SL#46_xGFR_inhibitors.sdf

References:

- 1 *Ups J Med Sci*. 2012 May; 117(2): 99–112, doi: 10.3109/03009734.2012.665097
2. *Curr Cancer Drug Targets*. 2012 March ; 12(3): 197–209

Contact us:

USA: +1 336 721 1617
Japan: +81-80-3401-9097
Europe/Global:

mparisi@asinex.com
sota@asinex.com
lsadovenko@asinex.com